{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01844661",
      "OrgStudyIdInfo": {
        "OrgStudyId": "EudraCT2008-000364-16"
      },
      "Organization": {
        "OrgFullName": "Hospital Infantil Universitario Niño Jesús, Madrid, Spain",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.",
      "OfficialTitle": "Phase 1 Trial of Celyvir in Children and Adults With Metastatic and Refractory Solid Tumors."
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2016",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 2013"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2014",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "January 2016",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "April 29, 2013",
      "StudyFirstSubmitQCDate": "April 29, 2013",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "May 1, 2013",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "February 18, 2016",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 19, 2016",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Manuel Ramírez, MD PhD",
        "ResponsiblePartyInvestigatorTitle": "Dr.",
        "ResponsiblePartyInvestigatorAffiliation": "Hospital Infantil Universitario Niño Jesús, Madrid, Spain"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Hospital Infantil Universitario Niño Jesús, Madrid, Spain",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Instituto de Salud Carlos III",
            "CollaboratorClass": "OTHER_GOV"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The investigators will evaluate the safety of weekly infusions (n=6) of CELYVIR in children and adults with metastatic and refractory solid tumors. CELYVIR consists in bone marrow-derived autologous mesenchymal stem cells (MSCs) infected with ICOVIR5, an oncolytic adenovirus. In addition to data on toxicities the investigators will evaluate clinical response."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Children",
          "Solid Tumors",
          "Metastases"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal stem cells",
          "Oncolytic adenovirus"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "CELYVIR",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Patients will received weekly (n=6) IV infusion of Celyvir.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: CELYVIR"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "CELYVIR",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "CELYVIR"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Bone marrow-derived autologous mesenchymal stem cells infected with ICOVIR5, an oncolytic adenovirus."
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Adverse effects after intravenous infusions",
            "PrimaryOutcomeDescription": "We will record any sign or symptom that could be related to the infusion of Celyvir.",
            "PrimaryOutcomeTimeFrame": "48 hours after each infusion"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Clinical outcome",
            "SecondaryOutcomeDescription": "Clinical outcome will be labelled as complete response, partial response, stable disease or disease progression.",
            "SecondaryOutcomeTimeFrame": "Up to 2 months after the last infusion"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nChildren: Up to 18 yrs. Refractory to at least 2 previous therapy lines. Life expectancy more than 6 months. Measurable disease.\nAdults: 18-75 yrs. Refractory to at least 2 previous therapy lines. ECOG (Eastern Cooperative Oncology Group) <2. Measurable disease.\n\nExclusion Criteria:\n\nPregnancy.\nCentral Nervous System metastasis.\nExperimental therapy during the previous month.\nChemotherapy less than 3 weeks previous.\nAny organ functionally impaired.\nConcurrent infectious disease.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "6 Months",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Manuel Ramírez, MD PhD",
            "OverallOfficialAffiliation": "Hospital Universitario Niño Jesús",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hospital Universitario Niño Jesús",
            "LocationCity": "Madrid",
            "LocationZip": "28009",
            "LocationCountry": "Spain"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "33737338",
            "ReferenceType": "derived",
            "ReferenceCitation": "Morales-Molina A, Gambera S, Leo A, García-Castro J. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma. J Immunother Cancer. 2021 Mar;9(3). pii: e001703. doi: 10.1136/jitc-2020-001703."
          },
          {
            "ReferencePMID": "32053771",
            "ReferenceType": "derived",
            "ReferenceCitation": "Ruano D, López-Martín JA, Moreno L, Lassaletta Á, Bautista F, Andión M, Hernández C, González-Murillo Á, Melen G, Alemany R, Madero L, García-Castro J, Ramírez M. First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors. Mol Ther. 2020 Apr 8;28(4):1033-1042. doi: 10.1016/j.ymthe.2020.01.019. Epub 2020 Jan 21."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009362",
            "ConditionMeshTerm": "Neoplasm Metastasis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009385",
            "ConditionAncestorTerm": "Neoplastic Processes"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11459",
            "ConditionBrowseLeafName": "Neoplasm Metastasis",
            "ConditionBrowseLeafAsFound": "Metastases",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M2762",
            "ConditionBrowseLeafName": "Adenoviridae Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11482",
            "ConditionBrowseLeafName": "Neoplastic Processes",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC01",
            "ConditionBrowseBranchName": "Infections"
          }
        ]
      }
    }
  }
}